Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 2/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.45 |
| ▸ | SUV39H2 | Q9H5I1 | 10/20 | 0.40 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.38 |
| ▸ | SKP1 | P63208 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.37 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.37 |
| ▸ | ITGAL | P20701 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30675193 | 1.00 | MAP4K4 (0.46) | MAP4K4PDE10ASUV39H2EIF2AK4CKS1B | |
| SCHEMBL26844190 | 0.87 | MAP4K4 (0.41) | MAP4K4PDE10AEIF2AK4 | |
| SCHEMBL26844199 | 0.81 | MAP4K4 (0.43) | MAP4K4PDE10ACKS1BSKP1SKP2 | |
| SCHEMBL30675155 | 0.81 | MAP4K4 (0.54) | MAP4K4SUV39H2CKS1BSKP1SKP2 | |
| SCHEMBL21060267 | 0.81 | MAP4K4 (0.54) | MAP4K4SUV39H2CKS1BSKP1SKP2 | |
| SCHEMBL21060497 | 0.78 | PARP1 (0.34) | MAP4K4PDE10ACKS1BSKP1SKP2 | |
| SCHEMBL30675187 | 0.78 | PARP1 (0.34) | MAP4K4PDE10ACKS1BSKP1SKP2 | |
| SCHEMBL21060471 | 0.76 | HSP90AA1 (0.40) | PDE10A | |
| SCHEMBL29897152 | 0.76 | HSP90AA1 (0.40) | PDE10A | |
| SCHEMBL21060496 | 0.75 | HTR6 (0.37) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820768-B2 | 4-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-21 | — | — | US | disclosed |
| EP-3728252-B1 | 4-AZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20220340555-A1 | 4-AZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-27 | — | — | US | disclosed |
| US-11053244-B1 | 4-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| EP-3728252-A1 | 4-AZAINDOLE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2020-10-28 | — | — | EP | disclosed |
| US-10730877-B2 | 4-Azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-04 | — | — | US | disclosed |
| US-20200095247-A1 | 4-AZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-03-26 | — | — | US | disclosed |
| US-10544143-B2 | 4-azaindole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190185469-A1 | 4-AZAINDOLE COMPOUNDS | SYNGENE INTERNATIONAL LIMITED (IN) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820768-B2 | 4-azaindole compounds | TLR7, TLR9, TLR5 | MAP4K4 1738/4885PDE10A 815/4885SUV39H2 3241/4885 |
| US-20220340555-A1 | 4-AZAINDOLE COMPOUNDS | TLR7, TLR9, TLR5 | MAP4K4 1738/4885PDE10A 815/4885SUV39H2 3241/4885 |
| US-11053244-B1 | 4-azaindole compounds | TLR7, TLR9, TLR5 | MAP4K4 1738/4885PDE10A 815/4885SUV39H2 3241/4885 |
| US-10544143-B2 | 4-azaindole compounds | TLR7, TLR9, TLR5 | MAP4K4 1738/4885PDE10A 815/4885SUV39H2 3241/4885 |
| US-10730877-B2 | 4-Azaindole compounds | TLR7, TLR9, TLR5 | MAP4K4 1738/4885PDE10A 815/4885SUV39H2 3241/4885 |
| US-20190185469-A1 | 4-AZAINDOLE COMPOUNDS | TLR7, TLR9, TLR5 | MAP4K4 1738/4885PDE10A 815/4885SUV39H2 3241/4885 |
| US-20200095247-A1 | 4-AZAINDOLE COMPOUNDS | TLR7, TLR9, TLR5 | MAP4K4 1738/4885PDE10A 815/4885SUV39H2 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.